About Protalix BioTherapeutics
Protalix BioTherapeutics is a company based in Karmiel (Israel) founded in 1993.. The company has 213 employees as of December 31, 2024. Protalix BioTherapeutics offers products and services including Elfabrio®, Elelyso®, and ProCellEx®. Protalix BioTherapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Karmiel, Israel
- Employees 213 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Protalix Biotherapeutics, Inc. (De)
-
Annual Revenue
$53.4 M-18.47as on Dec 31, 2024
-
Net Profit
$2.93 M-64.73as on Dec 31, 2024
-
EBITDA
$5.22 M-55.19as on Dec 31, 2024
-
Latest Funding Round
$43.7 M (USD), Post-IPO
Mar 12, 2020
-
Investors
UBS
& 11 more
-
Employee Count
213
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Protalix BioTherapeutics
Protalix BioTherapeutics is a publicly listed company on the AMEX with ticker symbol PLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Protalix BioTherapeutics
Protalix BioTherapeutics offers a comprehensive portfolio of products and services, including Elfabrio®, Elelyso®, and ProCellEx®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats Fabry disease through recombinant protein administration.
Addresses Gaucher disease with therapeutic protein solutions.
Enables plant-based production of recombinant therapeutic proteins.
Unlock access to complete
Leadership Team
7 people
Software Development Team
5 people
Scientific Team
3 people
Finance and Accounting
2 people
Operations Team
2 people
Human Resources and Administration
2 people
Senior Team
2 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Protalix BioTherapeutics
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $43.7M
-
First Round
First Round
(15 Oct 2004)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Post-IPO - Protalix BioTherapeutics | Valuation |
investors |
|
| Jan, 2017 | Amount | Grant - Protalix BioTherapeutics | Valuation |
investors |
|
| Oct, 2015 | Amount | Post-IPO - Protalix BioTherapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Protalix BioTherapeutics
Protalix BioTherapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include UBS, Pfizer and Mor Investment House. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-short strategy hedge fund and venture capital firm investing in tech companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are directed toward Israeli technology startups by Docor.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Protalix BioTherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Protalix BioTherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Protalix Biotherapeutics Comparisons
Competitors of Protalix BioTherapeutics
Protalix BioTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Protalix Biotherapeutics
Frequently Asked Questions about Protalix BioTherapeutics
When was Protalix BioTherapeutics founded?
Protalix BioTherapeutics was founded in 1993 and raised its 1st funding round 11 years after it was founded.
Where is Protalix BioTherapeutics located?
Protalix BioTherapeutics is headquartered in Karmiel, Israel. It is registered at Karmiel, Northern District, Israel.
How many employees does Protalix BioTherapeutics have?
As of Dec 31, 2024, the latest employee count at Protalix BioTherapeutics is 213.
What is the annual revenue of Protalix BioTherapeutics?
Annual revenue of Protalix BioTherapeutics is $53.4M as on Dec 31, 2024.
What does Protalix BioTherapeutics do?
Protalix BioTherapeutics was founded in 1993 in Karmiel, Israel, and operates in the biotechnology sector. Recombinant proteins are developed and commercialized using the ProCellEx plant cell expression system. A pipeline of novel and biosimilar proteins is pursued, with ELELYSO marketed as a glucocerebrosidase enzyme for Type 1 Gaucher disease. Additional recombinant proteins are under development for Fabry disease, immune and inflammatory conditions, and cystic fibrosis.
Who are the top competitors of Protalix BioTherapeutics?
Protalix BioTherapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Protalix BioTherapeutics offer?
Protalix BioTherapeutics offers Elfabrio®, Elelyso®, and ProCellEx®.
Is Protalix BioTherapeutics publicly traded?
Yes, Protalix BioTherapeutics is publicly traded on AMEX under the ticker symbol PLX.
Who are Protalix BioTherapeutics's investors?
Protalix BioTherapeutics has 12 investors. Key investors include UBS, Pfizer, Mor Investment House, European Union, and Alrov.
What is Protalix BioTherapeutics's ticker symbol?
The ticker symbol of Protalix BioTherapeutics is PLX on AMEX.